MBRX Reports MIRACLE Trial CRc >40% (≈67% vs SOC), CR ~30%, 56/90 AML pts Enrolled, Unblinding Expected Q2 2026
Moleculin Biotech, Inc. · PHARMACEUTICAL PREPARATIONS · Now $2.64
+12% in 7d after detection
Post-detection moves
1h
—
1d
+2.8%
3d
-2.3%
7d
+12%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS